Drugs / [99mTc]Tc(CO)3-(HE)3-Ec1
[99mTc]Tc(CO)3-(HE)3-Ec1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05620472 | Oct 2022 → Dec 2024 | cancer | Tomsk National Research Medical Center of the Russian Academy of Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [99mTc]Tc(CO)3-(HE)3-Ec1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05620472 ↗ |
| Modality | Diagnostic / imaging agent | “SPECT Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 in Solid Tumors Patients” NCT05620472 ↗ |
| Route | Intravenous | “single intravenous administration” NCT05620472 ↗ |